AirSculpt Technologies (NASDAQ:AIRS) Major Shareholder Jorey Chernett Buys 90,000 Shares

AirSculpt Technologies, Inc. (NASDAQ:AIRS) major shareholder Jorey Chernett acquired 90,000 shares of the stock in a transaction that occurred on Friday, April 3rd. The stock was purchased at an average price of $2.82 per share, for a total transaction of $253,800.00. Following the completion of the purchase, the insider directly owned 6,933,761 shares in the company, valued at $19,553,206.02. This trade represents a 1.32% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Monday, March 23rd, Jorey Chernett acquired 50,000 shares of AirSculpt Technologies stock. The stock was purchased at an average price of $2.91 per share, for a total transaction of $145,500.00.
• On Friday, March 20th, Jorey Chernett acquired 40,000 shares of AirSculpt Technologies stock. The stock was purchased at an average price of $2.77 per share, for a total transaction of $110,800.00.
• On Thursday, March 19th, Jorey Chernett acquired 77,702 shares of AirSculpt Technologies stock. The stock was purchased at an average price of $2.64 per share, for a total transaction of $205,133.28.
• On Tuesday, March 17th, Jorey Chernett acquired 83,000 shares of AirSculpt Technologies stock. The stock was purchased at an average price of $2.56 per share, for a total transaction of $212,480.00.
• On Monday, March 16th, Jorey Chernett acquired 105,848 shares of AirSculpt Technologies stock. The stock was purchased at an average price of $2.43 per share, for a total transaction of $257,210.64.
• On Wednesday, March 11th, Jorey Chernett bought 88,000 shares of AirSculpt Technologies stock. The shares were acquired at an average cost of $2.15 per share, for a total transaction of $189,200.00.
• On Friday, March 6th, Jorey Chernett bought 45,600 shares of AirSculpt Technologies stock. The shares were acquired at an average cost of $2.00 per share, for a total transaction of $91,200.00.
• On Wednesday, March 4th, Jorey Chernett bought 30,000 shares of AirSculpt Technologies stock. The shares were acquired at an average cost of $1.87 per share, for a total transaction of $56,100.00.
• On Tuesday, March 3rd, Jorey Chernett bought 80,000 shares of AirSculpt Technologies stock. The shares were acquired at an average cost of $1.71 per share, for a total transaction of $136,800.00.

AirSculpt Technologies Trading Down 2.2%

Shares of AIRS stock opened at $3.10 on Tuesday. The company’s fifty day simple moving average is $2.34 and its two-hundred day simple moving average is $4.32. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.51 and a quick ratio of 0.51. AirSculpt Technologies, Inc. has a 1 year low of $1.51 and a 1 year high of $12.00. The stock has a market capitalization of $218.71 million, a price-to-earnings ratio of -16.31 and a beta of 2.22.

AirSculpt Technologies (NASDAQ:AIRS) last issued its earnings results on Thursday, April 2nd. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. AirSculpt Technologies had a negative net margin of 11.41% and a negative return on equity of 14.30%. The business had revenue of $33.44 million for the quarter, compared to analysts’ expectations of $34.93 million. During the same quarter in the previous year, the firm posted ($0.09) EPS. The business’s revenue for the quarter was down 14.8% compared to the same quarter last year. As a group, analysts anticipate that AirSculpt Technologies, Inc. will post -0.01 earnings per share for the current year.

Analyst Ratings Changes

AIRS has been the topic of several analyst reports. Wall Street Zen upgraded AirSculpt Technologies from a “sell” rating to a “hold” rating in a research report on Sunday. Weiss Ratings reiterated a “sell (d-)” rating on shares of AirSculpt Technologies in a research report on Monday, December 29th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $6.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in shares of AirSculpt Technologies in the fourth quarter worth approximately $30,000. Millennium Management LLC bought a new position in shares of AirSculpt Technologies in the fourth quarter worth approximately $33,000. Aigen Investment Management LP bought a new position in shares of AirSculpt Technologies in the fourth quarter worth approximately $36,000. Wells Fargo & Company MN increased its position in shares of AirSculpt Technologies by 49.9% in the fourth quarter. Wells Fargo & Company MN now owns 19,275 shares of the company’s stock worth $38,000 after purchasing an additional 6,420 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of AirSculpt Technologies by 239.5% in the third quarter. BNP Paribas Financial Markets now owns 5,952 shares of the company’s stock worth $48,000 after purchasing an additional 4,199 shares during the last quarter. Institutional investors own 91.54% of the company’s stock.

About AirSculpt Technologies

AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.

Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.